We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+16.83%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.49B
AUM Growth
+$21.6M
Cap. Flow
+$155M
Cap. Flow %
6.21%
Top 10 Hldgs %
58.42%
Holding
119
New
16
Increased
22
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$27.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$23.7M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.2M
4
MDCO
Medicines Co
MDCO
+$16M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$14.8M

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$37M
2
AVTR icon
Avantor
AVTR
+$16.9M
3
Z icon
Zillow
Z
+$13.9M
4
BPMC
Blueprint Medicines
BPMC
+$13M
5
HTHT icon
Huazhu Hotels Group
HTHT
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 49.17%
2 Consumer Discretionary 26.12%
3 Technology 2.9%
4 Communication Services 0.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACET icon
76
Adicet Bio
ACET
$76.1M
$4.42M 0.18%
4,464
+1,250
+39% +$1.4M
BBIO icon
77
BridgeBio Pharma
BBIO
$16.5B
$4.29M 0.17%
200,000
– –
ORTX
78
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$4.16M 0.17%
35,000
– –
FOLD
79
CALL
DELISTED
Amicus Therapeutics
FOLD
$4.01M 0.16%
+500,000
New +$5.43M
KURA icon
80
Kura Oncology
KURA
$787M
$3.79M 0.15%
+250,000
New +$4.45M
STML
81
DELISTED
Stemline Therapeutics, Inc.
STML
$3.75M 0.15%
360,000
– –
RNAC icon
82
Cartesian Therapeutics
RNAC
$216M
$3.67M 0.15%
70,000
– –
SGMO
83
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.67M 0.15%
405,000
– –
IGMS
84
DELISTED
IGM Biosciences
IGMS
$3.55M 0.14%
+200,000
New +$4.04M
DOYU
85
DouYu International Holdings
DOYU
$140M
$3.28M 0.13%
+40,000
New +$3.69M
ALEC icon
86
Alector
ALEC
$169M
$3.25M 0.13%
225,000
– –
YI
87
111 Inc
YI
$33.4M
$3.17M 0.13%
65,000
+20,000
+44% +$795K
NIO icon
88
NIO
NIO
$11.9B
$3.12M 0.13%
2,000,000
-2,850,000
-59% -$8.72M
ARAV
89
DELISTED
Aravive, Inc. Common Stock
ARAV
$3M 0.12%
400,000
+92,534
+30% +$577K
NIO icon
90
CALL
NIO
NIO
$11.9B
$2.73M 0.11%
1,750,000
– –
ALLO icon
91
Allogene Therapeutics
ALLO
$597M
$2.73M 0.11%
100,000
-100,000
-50% -$2.85M
AXLA
92
DELISTED
Axcella Health Inc. Common Stock
AXLA
$2.55M 0.1%
18,000
+2,410
+15% +$446K
VKTX icon
93
Viking Therapeutics
VKTX
$3.83B
$2.41M 0.1%
350,000
+250,000
+250% +$1.86M
TWST icon
94
Twist Bioscience
TWST
$5.21B
$2.39M 0.1%
100,000
– –
SYRE icon
95
Spyre Therapeutics
SYRE
$8.28B
$2.31M 0.09%
12,000
+5,242
+78% +$1.02M
GRTS
96
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$2.16M 0.09%
250,000
-250,000
-50% -$2.53M
CLVS
97
DELISTED
Clovis Oncology, Inc.
CLVS
$1.97M 0.08%
+500,000
New +$4.04M
XYZ
98
Block Inc
XYZ
$49.1B
$1.86M 0.07%
+30,000
New +$2.04M
AKBA icon
99
Akebia Therapeutics
AKBA
$335M
$1.67M 0.07%
425,000
– –
KDNY
100
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.06M 0.04%
200,000
– –
1 2 3
4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2019 Portfolio in Review

As of Q3 2019, Artal Group held 119 positions worth $2.49B, up 0.87% from $2.47B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Artal Group deployed $155M of net new capital in Q3 2019, opening 16 new positions and adding to 22 existing holdings. Its largest new stake was Global Blood Therapeutics, Inc.: 350,000 shares worth $17M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 63% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was NVIDIA, an estimated $37M trimmed.

  • Artal Group's largest Q3 2019 buy was Global Blood Therapeutics, Inc.: 350,000 shares worth $17M.
  • Artal Group added most to Morphic Holding, Inc. Common Stock in Q3 2019, an estimated $27.6M increase.
  • Artal Group's biggest Q3 2019 reduction was NVIDIA, cutting an estimated $37M.
  • Artal Group fully exited Huazhu Hotels Group in Q3 2019, selling an estimated $12.7M.
  • Artal Group's ten largest holdings make up 58% of its $2.49B portfolio in Q3 2019.
  • Artal Group opened 16 new positions and closed 17 in Q3 2019.
  • Artal Group's portfolio value rose 0.87% quarter-over-quarter to $2.49B.

Based on Artal Group's 13F filing for Q3 2019, filed 14 Nov 2019.